Reperfusion Therapy in Acute Ischemic Stroke With Unclear Onset (RESTORE)
2010年6月4日 更新者:Asan Medical Center
REperfusion Therapy in Acute Ischemic STroke With Unclear Onset by MRI Evaluation
This study will test the hypothesis whether patients with unclear-onset stroke (UnCLOS) treated with thrombolysis could achieve a prespecified rate of good clinical outcome.
The secondary hypothesis is that the efficacy outcomes in UnCLOS group would be superior to those in historical UnCLOS group from prospective stroke registries.
研究概览
地位
完全的
条件
详细说明
- Study design: A prospective multicenter trial
- Study centers: 6 participating medical centers in South Korea
- Participants: Consecutive patients with acute ischemic stroke visiting the emergency room within 6 hours of the detection of stroke symptoms
Methods
3 thrombolysis protocols applicable to UnCLOS patients
- IV tissue plasminogen activator (tPA) : Conventional intravenous tPA (0.9 mg/kg, 10% of the dose as a bolus and the remainder over 60 minutes) will be administered to patients within 3 hours of first found abnormal time who had no arterial occlusion or catheter-inaccessible occlusion.
- IV tPA + IA urokinase protocol : Combined intravenous tPA (0.6 mg/kg, 10% of the dose as a bolus and the remainder over 30 minutes) with intra-arterial urokinase will be administered to those within 3 hours from first found abnormal time who had catheter-accessible arterial occlusion.
- IA UK protocol : Intra-arterial urokinase will be given to those between 3 and 6 hours after first found abnormal time who had catheter-accessible arterial occlusion.
Outcome variables
- Safety outcomes Symptomatic intracranial hemorrhage (ICH) within 48 hours from thrombolytic therapy.
Efficacy outcomes
- Long-term clinical outcomes (modified Rankin Scale) at 3 months
- Secondary efficacy outcomes : Good vs. Poor outcomes according to mRS responder analysis, Early neurological improvement, Immediate and 5-day recanalization on MRA or CTA
研究类型
观察性的
注册 (实际的)
83
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 85年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
非概率样本
研究人群
Consecutive patients with acute ischemic stroke visiting the ER within 6 hours of the detection of stroke symptoms will be screened for this study.
描述
Inclusion Criteria:
- The patient is male or female and age between 18 and 85 years
- The patient has unclear onset stroke
- Treatment of the patient can be initiated within 6 hours after first found abnormal time
- The patient has imaging-defined penumbra (at least 20%), measured by diffusion- and perfusion-weighted MRI
Exclusion Criteria:
- The patient has minor neurologic deficits (NIHSS <4, except aphasia or hemianopia).
- The patient has rapidly resolving neurological symptoms and the rate of improvement is projected to give the patient an NIHSS score <4 at the time of treatment.
- The patient has a pre-stroke mRS score of >1 (indicating previous disability).
- The symptoms of stroke are suggestive of subarachnoid hemorrhage.
- Evidence of infective endocarditis or septic embolism
- The patient has a history or clinical presentation of ICH, SAH, or AVM.
- Serious head trauma within 6 weeks
- Prior ischemic stroke in previous 6 weeks (except small infarct)
- Myocardial infarction in the previous 3 weeks
- Gastrointestinal or urinary tract bleeding in previous 21 days
- Major surgery in the previous 14 days
- History of biopsy of a parenchymal organ, trauma with internal organ injury or lumbar puncture within 14 days
- Arterial puncture at a non-compressible site in the previous 7 days
- Uncontrolled high blood pressure (systolic > 185 mmHg or diastolic > 110 mmHg on 3 separate occasions at least 10 min apart despite appropriate treatment)
- Evidence of active bleeding or acute trauma (fracture) on examination
- Current use of oral anticoagulants and a prolonged prothrombin time (INR >1.7)
- The patient has been treated with heparin in the previous 48 hours with prolonged aPTT, except for low dose subcutaneous LMWH with doses recommended for DVT prophylaxis
- Baseline platelet count < 100,000 mm3
- Baseline hematocrit < 25%
- Blood glucose concentration < 50 mg/dL (2.7 mmol/L) in case of CT screening
- Seizure at onset with postictal residual neurological impairments in case of CT screening
- The patient has a terminal illness.
- The patient is, in the opinion of the investigator, unlikely to comply with the clinical study protocol or is unsuitable for any other reason.
- The patient has extensive early infarction in any affected area defined as an infarcted core involving > 1/3 of MCA territory or the entire ACA or PCA territory
- The patient has well-developed parenchymal hyperintensity on FLAIR, T2*, or EPI-T2 images, or marked hypodensity on CT, indicative of subacute infarction, or enhancement with morphologic features suggesting the lesion is more than 6 hours old
- The patient has a contraindication to the imaging techniques (this means ferromagnetic objects for MRI, contraindications to contrast agent, renal disease with iodinated contrast agent in perfusion CT and CTA, etc.)
- The patient has imaging evidence of ICH or SAH, AVM, brain tumor (Incidental meningioma and microbleeds are not exclusion criteria. Incidental unruptured aneurysm that is small (< 5mm) is not an exclusion criterion).
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Acute ischemic stroke patients with unclear onset
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Good clinical outcome defined as modified Rankin Scale 0-2
大体时间:3 months after treatment
|
3 months after treatment
|
|
Symptomatic intracranial hemorrhage
大体时间:48 hours after treatment
|
48 hours after treatment
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2006年10月1日
初级完成 (实际的)
2009年6月1日
研究完成 (实际的)
2009年6月1日
研究注册日期
首次提交
2010年6月4日
首先提交符合 QC 标准的
2010年6月4日
首次发布 (估计)
2010年6月7日
研究记录更新
最后更新发布 (估计)
2010年6月7日
上次提交的符合 QC 标准的更新
2010年6月4日
最后验证
2006年10月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.